Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ)
CNY 13.18
(1.07%)
CNY 13.18
(1.07%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 3.95 Billion | 3.77 Billion | 3.33 Billion | 3.25 Billion | 3.64 Billion | 2.94 Billion |
| Cost of Revenue | 2.04 Billion | 1.76 Billion | 1.47 Billion | 1.27 Billion | 1.27 Billion | 1.03 Billion |
| Gross Profit | 1.9 Billion | 2.01 Billion | 1.86 Billion | 1.98 Billion | 2.37 Billion | 1.9 Billion |
| Operating Expenses | 1.32 Billion | 1.35 Billion | 1.25 Billion | 1.41 Billion | 1.83 Billion | 1.53 Billion |
| Selling, General and Administrative Expenses | 959.15 Million | 851.67 Million | 821.16 Million | 1.03 Billion | 1.41 Billion | 1.15 Billion |
| Research and Development Expenses | 371.78 Million | 367.06 Million | 329.33 Million | 259.24 Million | 254.1 Million | 242.01 Million |
| Other Expenses | 6.35 Million | 135.65 Million | 99.75 Million | 114.69 Million | 172.11 Million | -852.17 Thousand |
| Cost and Expenses | 3.28 Billion | 3.12 Billion | 2.72 Billion | 2.68 Billion | 3.11 Billion | 2.57 Billion |
| Operating Income | 714.05 Million | 756.61 Million | 692.96 Million | 765.38 Million | 602.06 Million | 416.29 Million |
| Interest Expense | 9.87 Million | 6.01 Million | 3.68 Million | 5.99 Million | 10.61 Million | 5.07 Million |
| Income Tax Expense | 84.62 Million | 82.49 Million | 79.77 Million | 105.65 Million | 81.46 Million | 43.95 Million |
| Earnings before Tax | 708.04 Million | 750.31 Million | 694.48 Million | 758.97 Million | 603.41 Million | 415.44 Million |
| Net Income | 618.89 Million | 662.25 Million | 612.54 Million | 653.07 Million | 520.39 Million | 370.03 Million |
| Earnings Per Share Basic | 0.72 | 0.77 | 0.75 | 0.83 | 0.64 | 0.43 |
| Earnings Per Share Diluted | 0.72 | 0.77 | 0.75 | 0.83 | 0.64 | 0.43 |
| Weighted Average Shares Outstanding | 859.58 Million | 860.06 Million | 816.72 Million | 791.19 Million | 814.42 Million | 867.19 Million |
| Weighted Average Shares Outstanding (Diluted) | 859.58 Million | 860.06 Million | 816.72 Million | 791.19 Million | 814.42 Million | 867.19 Million |
| Gross Margin | 0.48 | 0.53 | 0.56 | 0.61 | 0.65 | 0.65 |
| EBIT Margin | 0.24 | 0.25 | 0.26 | 0.27 | 0.20 | 0.18 |
| Profit Margin | 0.16 | 0.18 | 0.18 | 0.20 | 0.14 | 0.13 |
| EBITDA | 945.42 Million | 962.17 Million | 893.02 Million | 927.31 Million | 726.26 Million | 523.41 Million |
| Earnings Before Tax Margin | 0.18 | 0.20 | 0.21 | 0.23 | 0.17 | 0.14 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 1.05 Billion | 1.07 Billion | 1.06 Billion | 1.05 Billion | 3.95 Billion | 988.98 Million |
| Cost of Revenue | 527.7 Million | 559.77 Million | 510.33 Million | 563.13 Million | 2.04 Billion | 475.19 Million |
| Gross Profit | 531.11 Million | 517.01 Million | 550.32 Million | 493.55 Million | 1.9 Billion | 513.79 Million |
| Operating Expenses | 345.3 Million | 327.31 Million | 353.32 Million | 398.18 Million | 1.32 Billion | 352.69 Million |
| Selling, General and Administrative Expenses | 435.01 Million | 239.35 Million | 259.98 Million | 241.76 Million | - | 328.69 Million |
| Research and Development Expenses | 72.41 Million | 91.3 Million | 98.38 Million | 133.79 Million | - | 88.33 Million |
| Other Expenses | -162.12 Million | 3.34 Million | 63.3 Thousand | -22.62 Million | 6.35 Million | 236.41 Thousand |
| Cost and Expenses | 873.01 Million | 887.08 Million | 863.66 Million | 961.32 Million | 3.37 Billion | 827.88 Million |
| Operating Income | 195.64 Million | 189.69 Million | 202.05 Million | 95.36 Million | 579.18 Million | 170.87 Million |
| Interest Expense | 1.16 Million | 2.35 Million | 3.73 Million | 1.07 Million | 7.31 Million | 1.75 Million |
| Income Tax Expense | 21.65 Million | 45.34 Million | 28.9 Million | 24.48 Million | 84.62 Million | 13.6 Million |
| Earnings before Tax | 196.34 Million | 278 Million | 202.11 Million | 171.94 Million | 714.08 Million | 171.1 Million |
| Net Income | 172.89 Million | 230.91 Million | 171.2 Million | 146.27 Million | 618.89 Million | 156.69 Million |
| Earnings Per Share Basic | 0.20 | 0.27 | 0.20 | 0.17 | - | 0.18 |
| Earnings Per Share Diluted | 0.20 | 0.27 | 0.20 | 0.17 | - | 0.18 |
| Weighted Average Shares Outstanding | 861.02 Million | 861.02 Million | 856.03 Million | 861.02 Million | 861.02 Million | 861.02 Million |
| Weighted Average Shares Outstanding (Diluted) | 861.02 Million | 861.02 Million | 856.03 Million | 861.02 Million | 861.02 Million | 861.02 Million |
| Gross Margin | 0.50 | 0.48 | 0.52 | 0.47 | 0.48 | 0.52 |
| EBIT Margin | 0.19 | 0.25 | 0.20 | 0.15 | - | 0.17 |
| Profit Margin | 0.16 | 0.21 | 0.16 | 0.14 | 0.16 | 0.16 |
| EBITDA | 197.5 Million | 265.34 Million | 210.76 Million | 153.24 Million | - | 170.81 Million |
| Earnings Before Tax Margin | 0.18 | 0.18 | 0.19 | 0.09 | 0.15 | 0.17 |
BKMM
TYX
033250
APEX
000816
BIRD